CoChat

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

Open access
The EINSTEIN Investigators · 2010 · New England Journal of Medicine

The DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1007903

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367

Cited by

See all 3,237

Metadata

Authors
The EINSTEIN Investigators
Corresponding author
The EINSTEIN Investigators
Venue
New England Journal of Medicine
Published
2010-12-23
Volume
363
Issue
26
Pages
2499-2510
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2115787552
Cited by
3,237
References
19
Citations by year
2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
FWCI
148.86
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Pure Amsterdam UMC (publishedVersion)
  • ORBi (University of Liège) (acceptedVersion, other-oa)
  • Murdoch University Research Portal (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
  • Flinders Academic Commons (Flinders University) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • IrInSubria (University of Insubria) (submittedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
MeSH terms
Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Rivaroxaban for Symptomatic Venous Thromboembolism. https://app.cochat.ai/papers/10.1056/nejmoa1007903
The paper
The EINSTEIN Investigators. (2010). Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1007903

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.